Human DNA topoisomerase II is an important target in anticancer therapy. Despite the
clinical success of drugs that target topoisomerase II, the development of resistant cancer …

Transporters in proximal renal tubules contribute to the disposition of numerous drugs.
Furthermore, the molecular mechanisms of tubular secretion have been progressively …

The use of chemical elixirs for the treatment of cancer can be traced through the medicinal
customs and practices of a number of cultures. 1 The modern use of pharmacologic agents …

Concise, efficient total syntheses of ningalin A (1), lamellarin O (2), lukianol A (3), and
permethyl storniamide A (5) are detailed on the basis of a common heterocyclic azadiene …

BMS-247550, a novel epothilone derivative, is being developed by Bristol-Myers Squibb
Company (BMS) as an anticancer agent for the treatment of patients with malignant tumors …

Resistance to chemotherapy is a major obstacle to the effective treatment of many tumor
types. Although many anticancer therapies can alter tumor growth, in most cases the effect is …

N-Acyl-2-aminothiazoles with nonaromatic acyl side chains containing a basic amine were
found to be potent, selective inhibitors of CDK2/cycE which exhibit antitumor activity in mice …

Purpose The ruthenium complex salt indazolium trans-[tetrachlorobisindazole-ruthenate
(III)](KP1019) and the analogous sodium salt KP1339 are effective tumor-inhibiting drugs in …

The transcription factor NF-κB has anti-apoptotic properties and may confer
chemoresistance to cancer cells. Here, we describe human pancreatic carcinoma cell lines …

High throughput screening identified 2-acetamido-thiazolylthio acetic ester 1 as an inhibitor
of cyclin-dependent kinase 2 (CDK2). Because this compound is inactive in cells and …